The Latest Breaking News from Summit Therapeutics

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

Summit Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Summit Therapeutics is a clinical-stage biotech company that has returned over 1,100% in 2024. Is the stock still a good buy right now?

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +1.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.30%. Stocks on Monday posted moderate gains on some dip buying following last Friday’s sharp...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.95%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.58%. Stocks today are moderately higher, recovering some of last Friday’s sharp sell-off on some...

With the Russell 2000 index taking a dip in 2024, these five top-rated RUT stocks are outshining their parent index and the broader market.

Caution: This company has had legal issues in the past. It is highly speculative. The Chart of the Day belongs to the oncology company Summit Therapeutics (SMMT) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha,...